Targets successfully addressed? Promising results? Just two patients have been treated. The second didn't respond and progressed with new liver/lung mets. As for the first patient, while she did have a durable response, she too progressed.

No offense (here comes the offense), but many long-term shareholders need a reality check. So far, the data doesn't mean much, if anything. What matters is the number, but considering how long it has taken them to dose patients they could be years away from anything that could be considered meaningful. Also, how long the raise will keep them going is another thing.